Abstract
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts a cancer cell-specific pro-apoptotic activity. This property made the TRAIL associated pathway one of the most promising strategies aimed at inducing tumor-selective death. In fact, several approaches have been considered to explore this pathway for cancer therapy, such as recombinant TRAIL, agonist antibodies for TRAIL receptors, and adenoviral TRAIL. However, all of these approaches have certain disadvantages that limit their clinical use. Our recent discovery that the complex PRAME/EZH2 is able to repress TRAIL expression, in a cancer-specific manner, suggests an alternative approach for combined cancer therapy. A genetic or pharmacological inhibition of TRAIL repressors in cancer cells could restore endogenous TRAIL expression, thereby overcoming some of the limitations of and/or cooperating with previous approaches.
Keywords: Apoptosis, cancer, EZH2, polycomb genes, PRAME, TRAIL, tumor necrosis factor, chromosome, natural killer cell, inflammation, autoimmune diseases, macrophages, metalloproteases, osteoprotegerin, conformational modification.
Current Molecular Medicine
Title:PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Volume: 13 Issue: 2
Author(s): D. D. De Carvalho, B. P. Mello, W. O. Pereira and G. P. Amarante-Mendes
Affiliation:
Keywords: Apoptosis, cancer, EZH2, polycomb genes, PRAME, TRAIL, tumor necrosis factor, chromosome, natural killer cell, inflammation, autoimmune diseases, macrophages, metalloproteases, osteoprotegerin, conformational modification.
Abstract: The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts a cancer cell-specific pro-apoptotic activity. This property made the TRAIL associated pathway one of the most promising strategies aimed at inducing tumor-selective death. In fact, several approaches have been considered to explore this pathway for cancer therapy, such as recombinant TRAIL, agonist antibodies for TRAIL receptors, and adenoviral TRAIL. However, all of these approaches have certain disadvantages that limit their clinical use. Our recent discovery that the complex PRAME/EZH2 is able to repress TRAIL expression, in a cancer-specific manner, suggests an alternative approach for combined cancer therapy. A genetic or pharmacological inhibition of TRAIL repressors in cancer cells could restore endogenous TRAIL expression, thereby overcoming some of the limitations of and/or cooperating with previous approaches.
Export Options
About this article
Cite this article as:
De Carvalho D. D., Mello P. B., Pereira O. W. and Amarante-Mendes P. G., PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy, Current Molecular Medicine 2013; 13 (2) . https://dx.doi.org/10.2174/1566524011313020006
DOI https://dx.doi.org/10.2174/1566524011313020006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review
Current Cancer Drug Targets Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry Mesothelioma - Update on Management
Current Respiratory Medicine Reviews VFP: A Visual Algorithm for Predicting Gene Fusion in RNA-Seq Data
Current Bioinformatics Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Anthracyclines: Selected New Developments
Current Medicinal Chemistry - Anti-Cancer Agents Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Aging and immunopathology in primary Sjögren's syndrome
Current Aging Science